These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction. Bonnier HJ; Visser RF; Klomps HC; Hoffmann HJ Am J Cardiol; 1988 Jul; 62(1):25-30. PubMed ID: 3289357 [TBL] [Abstract][Full Text] [Related]
3. Reperfusion in acute myocardial infarction. A multicentre randomised trial of early intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in the United States. Anderson JL Drugs; 1987; 33 Suppl 3():154-62. PubMed ID: 3315584 [TBL] [Abstract][Full Text] [Related]
4. An interim report of the efficacy and safety of anisoylated plasminogen streptokinase activator complex (APSAC). Johnson ES; Cregeen RJ Drugs; 1987; 33 Suppl 3():298-311. PubMed ID: 3315612 [TBL] [Abstract][Full Text] [Related]
5. Comparison of intravenous anisoylated plasminogen streptokinase activator complex with intracoronary streptokinase in acute myocardial infarction. Bonnier JJ Drugs; 1987; 33 Suppl 3():151-3. PubMed ID: 3315583 [TBL] [Abstract][Full Text] [Related]
6. Tolerance and complications in a multicenter trial of intravenous APSAC and intracoronary streptokinase in acute myocardial infarction. Rothbard RL; Anderson JL; Fitzpatrick PG; Hakworthy RA; Sorensen SG; Marder VJ Clin Cardiol; 1990 Mar; Suppl 5():V11-4; discussion V27-32. PubMed ID: 2182234 [TBL] [Abstract][Full Text] [Related]
7. Electrocardiographic and enzymatic infarct size in a randomised study of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. Hackworthy RA; Sorensen SG; Menlove RL; Anderson JL Drugs; 1987; 33 Suppl 3():198-208. PubMed ID: 3315592 [TBL] [Abstract][Full Text] [Related]
8. Effect of reperfusion on electrocardiographic and enzymatic infarct size: results of a randomized multicenter study of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) versus intracoronary streptokinase in acute myocardial infarction. Hackworthy RA; Sorensen SG; Fitzpatrick PG; Barry WH; Menlove RL; Rothbard RL; Anderson JL Am Heart J; 1988 Oct; 116(4):903-14. PubMed ID: 3051985 [TBL] [Abstract][Full Text] [Related]
9. Development and evaluation of anisoylated plasminogen streptokinase activator complex (APSAC) as a second generation thrombolytic agent. Anderson JL J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):22B-27B. PubMed ID: 3312369 [TBL] [Abstract][Full Text] [Related]
13. Anisoylated plasminogen streptokinase activator complex versus placebo. A preliminary multicentre study of safety and early mortality in acute myocardial infarction. Julian DG; Borthwick LS; Reid D; Jennings KP; Wainwright RJ; Rodger JC; Wood D; Phillips WS Drugs; 1987; 33 Suppl 3():261-7. PubMed ID: 3315604 [TBL] [Abstract][Full Text] [Related]
14. Coronary thrombolysis during acute myocardial infarction by intravenous BRL 26921, a new anisoylated plasminogen-streptokinase activator complex. Kasper W; Meinertz T; Wollschläger H; Bonzel T; Wolff P; Drexler H; Hofmann T; Zeiher A; Just H Am J Cardiol; 1986 Sep; 58(6):418-21. PubMed ID: 3529908 [TBL] [Abstract][Full Text] [Related]
15. Safety and tolerance data from the Belgian multicentre study of anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction. Bossaert LL Drugs; 1987; 33 Suppl 3():287-92. PubMed ID: 3315610 [TBL] [Abstract][Full Text] [Related]
16. Safety and side effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study. Monassier JP; Hanssen M Drugs; 1987; 33 Suppl 3():282-5. PubMed ID: 3315608 [TBL] [Abstract][Full Text] [Related]
17. Early clinical evaluation of the intravenous treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex. Kasper W; Meinertz T; Wollschläger H; Bonzel T; Chen C; Hofmann T; Zeiher A; Drexler H; Just H Drugs; 1987; 33 Suppl 3():112-6. PubMed ID: 3315575 [TBL] [Abstract][Full Text] [Related]
18. Multicenter trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: effects on infarct size and left ventricular function. Bassand JP; Machecourt J; Cassagnes J; Anguenot T; Lusson R; Borel E; Peycelon P; Wolf E; Ducellier D J Am Coll Cardiol; 1989 Apr; 13(5):988-97. PubMed ID: 2647817 [TBL] [Abstract][Full Text] [Related]
19. Rapid lysis of coronary artery thrombi with anisoylated plasminogen: streptokinase activator complex. Treatment by bolus intravenous injection. Marder VJ; Rothbard RL; Fitzpatrick PG; Francis CW Ann Intern Med; 1986 Mar; 104(3):304-10. PubMed ID: 3511819 [TBL] [Abstract][Full Text] [Related]
20. Reperfusion, patency and reocclusion with anistreplase (APSAC) in acute myocardial infarction. Anderson JL Am J Cardiol; 1989 Jul; 64(2):12A-17A; discussion 24A-26A. PubMed ID: 2662737 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]